Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Market & Industry Briefs

Executive Summary

Brief summaries of recent medtech market and industry developments. This month we cover a new GAO report that ups the pressure on the medical imaging market; Cordis Corp.'s suspension of its PFO closure device program; Atritech's PMA for stroke prevention; Zimmer's acquisition of Abbott Spine; and the US market for contraception devices and procedures.

You may also be interested in...



Health Care Trends: Cost Control Measures in Full Swing

Affordability drives medical devices purchases and use. Even the most remarkable devices can see a tremendous downturn in usage is reimbursement is lowered. That's why an an annoucement that CMS is considering changes to coverage of certain medical procedures is making device company CEOs more than a little nervous.

Health Care Trends: Cost Control Measures in Full Swing

Affordability drives medical devices purchases and use. Even the most remarkable devices can see a tremendous downturn in usage is reimbursement is lowered. That's why an an annoucement that CMS is considering changes to coverage of certain medical procedures is making device company CEOs more than a little nervous.

PFO Closure: Challenges and Opportunities

Over the past several years, device manufacturers have introduced a number of PFO closure devices in Europe, but conducting randomized trials to gain US market approval has proven to be a much more difficult endeavor. Companies have experienced numerous delays and setbacks in both their stroke and migraine programs. The good news: setbacks for some could also boost randomized migraine studies still ongoing by other competitors in this field.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

MT035204

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel